You are here

Coronary Intervention & Surgery

 - consent

Patients who were more fully informed about angiography and the possibility of PCI were more likely to decide against it, a study published online May 18 in JAMA Internal Medicine found. Overall, the cardiologist-patient discussions were short and incomplete.

 - Smoking

More than a quarter of patients undergoing PCI are smokers at the time of treatment. If they quit smoking following the procedure, they are more likely to have improvements in quality of life and have less chest pain and angina than if they continue to smoke, according to a prospective analysis of a PCI registry.

 - treadmill

Only about 60 percent of PCI patients get referred to a cardiac rehabilitation program, according to a recent study, and the barrier is more likely due to hospital characteristics than insurance. 

 - Medication Management

Cardiologists in real-world practice may not be optimizing the benefit of prasugrel in patients undergoing PCI but they also don’t appear to be putting them in harm’s way, according to results released May 8 at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 scientific session in San Diego.

 - Diamondback handle

An atherectomy device that “sands” calcified lesions in coronary arteries before stenting proved to be effective and durable at two years, and possibly even cost-effective, in a late-breaking clinical trial unveiled on May 7.

 

More Stories

Diabetes patients undergoing CABG have increased risk of death

Patients with type 1 diabetes had double the risk of death after undergoing CABG compared with a group that did not have diabetes, according to an observational, nationwide population-based cohort study.

Potential harms from cath lab radiation may include heart disease

Interventional cardiologists and nurses worry about cardiovascular disease developing in their patients. A study that looked at long-term radiation exposure to cath lab operators and staff may prompt them to add themselves to that list.

OriGen Biomedical recalls ECMO catheters

OriGen Biomedical voluntarily recalled a lot of its 51 VV13F Reinforced Dual Lumen ECMO Catheters, according to the company and the FDA.

NIH launches largest trial to date for HIV-related cardiovascular disease

The NIH has launched a randomized, multicenter, international study to see if statins can reduce the risk of cardiovascular disease in HIV patients. As of now, no therapies have been found to lower cardiovascular risk in this patient population.

FDA advisory committee recommends approval of cangrelor

An FDA advisory panel recommended the approval of cangrelor to reduce the risk of periprocedural thrombotic events in patients with coronary artery disease undergoing PCI.

PROMETHEUS, ORBIT II, TRIAGE among SCAI's late-breakers

The Society for Cardiovascular Angiography and Interventions’ (SCAI) 2015 scientific session will flash some big names on its marque this year, with PROMETHEUS, ORBIT II and other trials scheduled to make an appearance.

Survey: Orthopedic injuries plague half of operators

Almost half of operators who responded to a survey on occupational health hazards in the cath lab reported they experienced at least one orthopedic injury, and more than one in 20 limited their case load because of radiation exposure.

Statement clarifies use of heart pumps in high-risk patients

Cardiologists trying to navigate the proper course of care for cardiac patients who might benefit from percutaneous mechanical circulatory support received a helping hand in the form of a consensus statement published online April 7. The document provides a roadmap for physicians until there is sufficient high-level evidence to inform guidelines.

Limb function, sensation not impinged by radial artery access

Chalk another one up for transradial access. According to results published online March 26, patients undergoing catheterization via the radial artery had no significant change to limb function and sensation, assessed by cold intolerance, was not adversely impacted.

Benefit of percutaneous heart pumps murky despite skyrocketing use

The use of percutaneous ventricular assist devices (PVADs) has grown by leaps and bounds in recent years, but a study published online March 30 in JAMA Internal Medicine casts doubt on their overall benefit, given the high costs and mortality rates.

Following STEMI PCI, discharge after 48 hours as safe as 3 to 4 days

Short hospital stays following PCI may be safe for older patients with STEMI. However, researchers caution stays of less than 48 hours may increase risk for 30-day mortality and major adverse cardiac events.

SCAI keynotes to emphasize tech, big data and research needs

The Society for Cardiovascular Angiography and Interventions’ (SCAI) 2015 convention will kick off May 6 with a session on state-of-the-art technologies, which will include keynote lectures by Christian Assad-Kottner, MD, of El Camino Hospital in Mountain View, Calif., and Peter J. Fitzgerald, MD, of Stanford University in California.

ACC.15: Upcoming PCI AUC take into account past criticisms

Acknowledging there was room for improvement, the authors of PCI appropriate use criteria (AUC) have applied lessons from the last set of guidelines in a revision scheduled for publication this year, a member of the writing committee said.

FDA clears Impella heart pump to assist in high-risk PCIs

The FDA granted Abiomed premarket approval for its Impella 2.5 heart pump for use during high-risk PCIs. The device provides temporary ventricular support.

TOTAL: Opening eyes but not shutting doors

The major scientific meetings often bill their late-breaking clinical trials as potentially practice-changing revelations. They certainly add insight, even when questions linger.

ACC.15: TOTAL provides clarity for interventional cardiologists

Cardiovascular Business met with Ajay J. Kirtane, MD, SM, from the Center for Interventional Vascular Therapy and chief academic officer at Columbia University Medical Center in New York City, on March 16, the closing day of the American College of Cardiology scientific session. Here is what he offered as highlights.

FDA recalls sheaths used for caths

The FDA issued a class 1 recall on Medtronic’s 10 French FlexCath Select Steerable Sheath, citing problems that may occur with the device outside a patient’s body.

Everolimus-eluting stent outcomes roll snake eyes in registry analysis

Contrary to previous gains with new interventional technology, data suggest that second-generation, everolimus-eluting stents have similar rates of death as CABG. Moreover, PCI with these stents had increased rates of MI and repeat revascularization but a lower rate of stroke. 

ACC.15: TOTAL raises flag over use of routine thrombectomy

TOTAL may not totally spell the end of routine manual thrombectomy with PCI, but it should make interventional cardiologists think twice about using it with STEMI patients. The large, international trial showed no clinical benefit and possible harm.

ACC.15: Do less testing & DAPT’s OK among trial takeaways

Jeffrey Cavendish, MD, of Kaiser Permanente in San Diego, shared his impressions of the first day of the American College of Cardiology’s (ACC) scientific session with Cardiovascular Business. His highlights touch on three Ps: prevention, PROMISE and PEGASUS.